Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02ERH
|
|||
| Former ID |
DIB015746
|
|||
| Drug Name |
EP-2060
|
|||
| Synonyms |
Apoptosis inducers, EpiCept; MX-11697; Anticancer agents, Celera/EpiCept; Apoptosis inducers, Celera/EpiCept; Apoptosis inducers, Celera/Maxim; Anti-cancer agents, Celera/Maxim
Click to Show/Hide
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Terminated | [1] | |
| Company |
Celera South San Francisco
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Protease unspecific (PRO) | Target Info | Inducer | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013537) | |||
| REF 2 | Discovery of 4-aryl-4H-chromenes as potent apoptosis inducers using a cell- and caspase-based Anti-cancer Screening Apoptosis Program (ASAP): SAR studies and the identification of novel vascular disrupting agents. Anticancer Agents Med Chem. 2009 May;9(4):437-56. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.